Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
New drug ambipor that is an immobilized antibacterial agent with local prolonged therapeutic activity was developed for prophylaxis of wound suppuration. In ambipor A drugs gentamicin, dioxidin, kephzol and riphampicin are immobilazed, in iodopor - iodine. Experimental studies on 455 white rats showed that ambipor prevents suppuration, abscess formation around ligatures, improve regeneration and fibrillogenesis. In clinical practice ambipor A and iodopor were used in 562 patients. Rate of suppuration decreased from 11.7 to 2.3% compared with control group of patients.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!